Clinical Trial Update: QT Interval Prolongation Study of Eribulin Mesylate (E7389) in Patients With Advanced Solid Tumors [Phase 1]

View source ↗

Summary

Phase 1 study evaluating the risk of QT interval prolongation with eribulin mesylate (E7389) in patients with advanced solid tumors; the study has completed and…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Solid Tumors

Drugs mentioned

• ERIBULIN MESYLATE (Eribulin mesylate)

Snippet

Sponsor: Eisai Limited | Conditions: Advanced Solid Tumor | Phase 1 | Status: COMPLETED | Results posted: 2012-04-13